Fexlamose

Investigational drug

Pharmaceutical compound

Fexlamose
Clinical data

Other names	AER-01; MUC-031
Identifiers
IUPAC name (2S,3S,4S,5R,6R)-2-(sulfanylmethyl)-6-[(2R,3R,4S,5S,6S)-3,4,5-trihydroxy-6-(sulfanylmethyl)oxan-2-yl]oxyoxane-3,4,5-triol
CAS Number	1285607-08-0
PubChem CID	172866809
ChemSpider	129998742
UNII	VY9GAK6EVR
Chemical and physical data
Formula	C₁₂H₂₂O₉S₂
Molar mass	374.42g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CS)O)O)O)O)O)O)S
InChI InChI=InChI=1S/C12H22O9S2/c13-5-3(1-22)19-11(9(17)7(5)15)21-12-10(18)8(16)6(14)4(2-23)20-12/h3-18,22-23H,1-2H2/t3-,4-,5-,6-,7+,8+,9-,10-,11-,12-/m1/s1 Key:LVLYFBOCRJBHIZ-LIZSDCNHSA-N

Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol–disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.^[1]^[2]

References

↑ "Fexlamose". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Cazzola M, Rogliani P, Ora J, Calzetta L, Matera MG (April 2026). "Mucus as a Treatable Trait in Chronic Airway Diseases". Drugs. 86 (4): 443–463. doi:10.1007/s40265-026-02294-1. PMC 13005781 . PMID 41712061.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.